Larazotide Acetate Dosage Chart - Dosage Peptide

Larazotide Acetate (AT-1001) Dosage Protocol

Larazotide acetate (AT-1001) is an oral, minimally-absorbed tight-junction–regulating peptide investigated for intestinal barrier function in celiac disease — investigational, not FDA-approved, and its Phase 3 celiac trial did not meet its primary endpoint.

Oral tight-junction regulator; studied as a zonulin antagonist that acts locally in the gut lumen with minimal systemic absorption.

Research doses cluster around 0.5 mg (500 mcg) three times daily before meals; the 0.5 mg arm — not higher doses — met the Phase 2b endpoint.

Oral peptide (capsule/solution). It is swallowed, not reconstituted or injected, and is designed to work at the intestinal surface.

As a lyophilized research peptide, generally kept cool and dry, protected from light and moisture, per supplier documentation.

Quickstart Highlights

Larazotide (larazotide acetate, developmental code AT-1001) is an eight-amino-acid oral, minimally-absorbed tight-junction regulator — a “zonulin antagonist” reverse-engineered from a fragment related to the Vibrio cholerae zonula occludens toxin to help stabilize, rather than open, the junctions between intestinal cells[1]. In the published literature it is investigated for intestinal barrier permeability — the “leaky gut” concept — and most rigorously as an add-on for celiac disease in patients who remain symptomatic despite a gluten-free diet[4].

Larazotide is investigational and not approved by the FDA or any major regulator for any indication; its Phase 3 celiac trial did not meet its primary endpoint and was discontinued in 2022. The figures below reflect published trial conventions and are provided strictly for research and educational reference — not medical advice or a recommendation to self-administer.

Supplies Needed

Because larazotide is oral and minimally absorbed, the practical considerations differ entirely from injectable peptides — there is no reconstitution, no syringe, and no sterile-injection step. Accurate sub-milligram measurement and meal-timing are what mattered in the studies.

Protocol Overview

At a reference maintenance amount of 0.5 mg three times daily, a single day’s documented exposure is ~1.5 mg. A 5 mg quantity therefore corresponds to only a few days of that per-meal schedule, which is why the trials relied on precisely dosed clinical formulations rather than bench-weighed powder.

Doses this small — 0.5 mg is 500 mcg — are difficult to measure accurately without an analytical balance. This is a real limitation for any bench work and one reason trial data cannot be assumed to transfer to unverified research material.

Dosing Protocol

A record of the amounts that appeared in the published celiac research, adapted to larazotide’s per-meal oral schedule. This is reference data to interpret the literature — not a protocol or a recommendation.

Most-studied maintenance

0.5 mg (500 mcg), 3× daily

Before meals; the dose that met the Phase 2b endpoint[3]

Lower Phase 3 arm

0.25 mg, 3× daily

Second low-dose arm in the CeD-Lara pivotal trial[7]

Higher maintenance tested

1 & 2 mg, 3× daily

Studied but did not outperform 0.5 mg[3]

Gluten-challenge doses

1, 4 & 8 mg, 3× daily

Used in controlled gluten-challenge trials; no clear added benefit[2]

Single-dose ceiling explored

12 mg (celiac); up to ~36 mg (healthy volunteers)

Highest single doses studied; no severe adverse effects reported[1]

Studied context

Add-on only

Always alongside a continued gluten-free diet — never as “permission” to eat gluten[4]

Why Larazotide draws research interest

These are the directions researchers and the peptide community most often explore Larazotide for — so you know you’re in the right place. They describe what is being studied, not proven benefits, approved uses, or promised results.

Intestinal barrier / 'leaky gut'

Investigated as a tool to modulate paracellular intestinal permeability and tight-junction integrity.

Celiac disease adjunct

Studied as an oral add-on to a gluten-free diet for persistent symptoms — investigational, Phase 3 endpoint not met.

Zonulin pathway

Used in research to probe the zonulin–tight-junction signaling hypothesis in gut barrier biology.

Gut-restricted peptide pharmacology

Examined as a model of a locally-acting, minimally-absorbed oral peptide.

Evidence ranges from early laboratory work to clinical trials depending on the use — the sections below cover the actual data and sources.

0.5 mg (500 mcg) per administration — the dose that met the Phase 2b endpoint; higher doses did not.[3]

Three times daily, taken orally alongside meals in the trial protocols.[3]

Shortly before meals, so the peptide is present in the gut lumen during gluten exposure — never injected, never reconstituted.

Investigational — a positive mid-stage signal that failed to replicate in a Phase 3 pivotal trial (discontinued 2022).[6]

Oral Dosing Guide

Larazotide is an oral, luminally-acting peptide, so its “dosing” is a record of what appeared in the trials rather than a titration schedule — and its most striking feature is an inverted dose-response, where the lowest maintenance dose is the one that worked.

Standard / Gradual Approach

Unlike systemic peptides that are stepped up gradually, larazotide was studied at fixed per-meal amounts. The widely referenced maintenance regimen is 0.5 mg (500 mcg) three times daily before meals, added on top of a continued gluten-free diet[3]. Higher amounts were not better: across trials, 1 mg and 2 mg three times daily — and the 1/4/8 mg doses used in gluten-challenge studies — did not outperform 0.5 mg, an atypical pattern researchers attribute to a surface-acting agent whose luminal effect may be self-limiting at higher concentrations[2][5].

Storage Instructions

As a peptide, larazotide is generally stored per supplier documentation — typically kept cool, dry, sealed, and protected from light and humidity, with lyophilized powder more stable than any solution.

Manufacturing-grade clinical material and unverified “research use only” powder are not equivalent in identity or purity; content and even correct identity are not guaranteed the way a GMP clinical supply would be.

Important Notes

Practical framing points that keep the record honest and consistent with how the molecule was actually developed.

▪Respect the route: Larazotide is an oral, luminally-acting peptide. Any protocol that describes reconstituting it with bacteriostatic water or injecting it is not grounded in the published research on this compound[4].

▪Meal timing is integral: In the trials the peptide was taken before eating so it was present at the gut surface when dietary antigens arrived — this was study design, not incidental[3].

▪Lower, not higher: The atypical dose-response means 0.5 mg was the effective maintenance dose while 1–2 mg were not — more is not better here[3].

▪Adjunct only: Larazotide was studied as an add-on to gluten avoidance — nothing in the data supports using it to tolerate gluten[4].

▪Lead with the Phase 3 miss: The most decisive data point is negative — the pivotal CeD-Lara trial did not meet its primary endpoint and was discontinued in 2022, so larazotide has no approved indication and no established consumer dosing[6].

How This Works

The intestinal lining is a single layer of epithelial cells sealed together by tight junctions that control the paracellular pathway — the space between cells — and thereby regulate what passes from the gut lumen into the tissue. When these junctions loosen, larger molecules such as gliadin fragments can cross more easily, which in a genetically susceptible person can drive the immune activation of celiac disease[8].

A proposed regulator of this process is zonulin, described as a physiological modulator of tight-junction assembly; in this model gliadin triggers zonulin release, which loosens the junctions and raises permeability[8]. Larazotide is studied as a zonulin antagonist / tight-junction regulator: in mechanistic work it is associated with promoting the reassembly of tight-junction proteins and the underlying actin cytoskeleton, blunting the gliadin- and zonulin-induced rise in permeability[4][5]. Because it acts at the epithelial surface and is minimally absorbed, it is framed as a “gut-restricted” agent — its intended pharmacology is at the tissue it touches, not throughout the body.

Lifestyle Factors

In every trial that defines this molecule, larazotide was an adjunct to a continued gluten-free diet — the strict avoidance of gluten remained the foundation, and the peptide was layered on top for patients who stayed symptomatic despite that diet[4].

Nothing in the data positions larazotide as a way to safely consume gluten; the trials that came closest were tightly controlled inpatient or protocolized gluten challenges, not everyday eating[2].

Potential Benefits & Side Effects

What the controlled human literature describes — framed honestly. Larazotide reached Phase 3 in celiac disease, further than most research peptides, but its strongest positive result was a single mid-stage endpoint that the pivotal trial failed to confirm.

Reported Effects

▪Persistent celiac symptoms: In a Phase 2b trial of 342 adults on a gluten-free diet ≥12 months, 0.5 mg three times daily significantly reduced average weekly symptom scores versus placebo (p=0.022) — the program’s high-water mark[3].

▪Gluten-induced immune activation: In controlled gluten-challenge studies larazotide attenuated some symptom and immunologic responses to gluten versus placebo, though barrier-permeability endpoints were mixed[2].

▪Intestinal permeability (“leaky gut”): It is a legitimate research probe of tight-junction/paracellular permeability, but the only rigorous clinical outcome data are in celiac disease — broad “heals leaky gut” claims outrun the science[5].

▪Not confirmed at the pivotal stage: The Phase 3 CeD-Lara trial (~525 patients) did not meet its primary endpoint and was discontinued in 2022 — a positive mid-stage signal that failed to replicate[6].

Common Side Effects

▪Generally well tolerated in trials: Across its clinical program larazotide had a safety profile broadly similar to placebo, with no signal of significant systemic toxicity — consistent with a minimally-absorbed, gut-restricted agent[1][4].

▪Tolerability is not efficacy: A compound can be well tolerated and still fail to work — larazotide’s core limitation is not a safety scare but that the pivotal trial did not show it helped patients[6].

▪Data describe a controlled population: The tolerability record reflects supervised use of a defined clinical formulation in monitored celiac patients — not unsupervised use of research-grade powder, other populations, other doses, or use beyond trial durations.

▪No regulatory vetting for consumer use: There is no approved label, no established consumer dosing, and no post-marketing safety surveillance, because larazotide was never approved.

▪Identity & purity caveat: “Research use only” larazotide is not a regulated pharmaceutical; content, purity, and even correct identity are not guaranteed, so trial data cannot be assumed to transfer to bench material.

Oral Administration

Oral administration is simple, but the meal-timing that defined the trials is the part that matters. Everything here is a description of the study protocol, not a recommendation to dose.

Before You Dose

▪Confirm the amount against the literature: the reference maintenance dose is 0.5 mg (500 mcg), a sub-milligram quantity that needs an accurate balance to measure.

▪Plan the dose to fall shortly before a meal, matching how the trials timed exposure to dietary antigens.

▪Keep the continued gluten-free diet as the foundation — in every study larazotide was an add-on, not a replacement for gluten avoidance.

Taking Your Dose

▪Take the oral dose (capsule/tablet form in the trials) by mouth — it is swallowed, never reconstituted or injected.

▪Administer it just before eating so the peptide is present in the gut lumen during the meal.

▪Repeat at the studied frequency of three times daily, spaced across the day’s main meals.

After Dosing

▪Do not double up after a missed dose; the trials used a fixed per-meal schedule, not catch-up dosing.

▪Reseal the container and return it to cool, dry, light-protected storage to preserve the peptide.

▪Track the record against the evidence — remembering that the decisive Phase 3 result was negative and larazotide remains investigational.

Recommended Source

For high-purity research peptides, we point researchers to Prime Lab Peptides for Larazotide (0.5 mg Capsules).

Why Prime Lab Peptides?

▪Top-rated on Trustpilot: Independently reviewed as the highest-rated peptide lab on Trustpilot — making it the best current source in the USA.

▪Third-party tested: Every batch ships with a Certificate of Analysis (COA) confirming purity and composition.

▪Consistent quality: ISO-aligned manufacturing and handling keep product integrity reliable batch to batch.

▪Cold-chain integrity: Temperature-controlled shipping and storage across the whole fulfilment chain.

▪Research-grade purity: Fit for educational and research use that demands high-quality peptides.

Note: Product availability and specifications subject to change. Verify current product details on supplier website.

References

View Source ↗

How to take Larazotide

1Confirm the capsule strength and your target dose from the schedule on this page (each capsule is a fixed strength).

2Take the required number of Larazotide capsules by mouth once daily, swallowed whole with water, with or without food.

3Keep the daily dose consistent and follow any documented gradual 4-week escalation steps.

4Store the capsules sealed at room temperature, dry and away from light — no mixing or refrigeration needed.

Larazotide — frequently asked questions

Larazotide is taken by mouth as one or more capsules once daily, swallowed whole with or without food. There is no mixing, reconstitution, or injection — it is an oral small-molecule compound, not an injectable peptide.

No. Because Larazotide is an oral capsule, none of the injectable-peptide supplies (bacteriostatic water, insulin syringes, alcohol swabs) apply — you simply take the capsule(s) by mouth.

Each capsule is a fixed strength, so a target dose is reached by taking the matching number of capsules at that strength. The dosing table on this page lists the reference dose for each step of a documented research schedule — match your capsule strength to it rather than assuming a fixed number.

Keep the capsules in their original sealed container at controlled room temperature, dry and away from heat, light and moisture, and follow the specific storage guidance supplied with your product. No refrigeration or reconstitution is required.

The main practical difference is the route of administration: Larazotide is swallowed as a capsule, so there is no reconstitution, bacteriostatic water, or sterile injection technique involved. Its specific mechanism of action and the research behind it are described in the "How This Works" section on this page.

No. Research-grade Larazotide is supplied strictly for laboratory and research purposes and is not an approved medicine for human use — regardless of whether an approved pharmaceutical product containing this ingredient exists. Everything here is research information, not medical advice; consult a licensed healthcare professional and the approved product labeling before any use.

New protocols & dosing updates

Reconstitution charts, new peptide protocols and safety updates — straight to your inbox. No spam, unsubscribe anytime.

Written by Dr. Aimen Arij, PharmD

More Immune & Gut protocols